Literature DB >> 31796924

Cut-price CAR-T cell therapies top India's biotech agenda.

Killugudi Jayaraman1.   

Abstract

Entities:  

Year:  2019        PMID： 31796924     DOI： 10.1038/s41587-019-0346-1

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

Review 1.  Equitable access to cell and gene therapies in South Africa: opportunities and hurdles.

Authors:  Candice Laverne Hendricks; Marco Alessandrini; Michael Sean Pepper
Journal:  Gene Ther       Date:  2022-01-08       Impact factor: 5.250

Review 2.  In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy.

Authors:  Tianqing Xin; Li Cheng; Chuchao Zhou; Yimeng Zhao; Zhenhua Hu; Xiaoyan Wu
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

Review 3.  Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Authors:  Dong-Rui Wang; Xian-Lin Wu; Ying-Li Sun
Journal:  Signal Transduct Target Ther       Date:  2022-09-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.